Determinants of activity of the HIV-1 maturation inhibitor PA-457.
about
Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv miceThe prototype HIV-1 maturation inhibitor, bevirimat, binds to the CA-SP1 cleavage site in immature Gag particlesPredicting Bevirimat resistance of HIV-1 from genotypeA single polymorphism in HIV-1 subtype C SP1 is sufficient to confer natural resistance to the maturation inhibitor bevirimatHIV type 1 Gag as a target for antiviral therapyVirus maturation as a new HIV-1 therapeutic targetPharmacological intervention of HIV-1 maturationNine crystal structures determine the substrate envelope of the MDR HIV-1 proteaseCharacterization of a novel type of HIV-1 particle assembly inhibitor using a quantitative luciferase-Vpr packaging-based assayStructural and functional insights into the HIV-1 maturation inhibitor binding pocketMechanistic Studies and Modeling Reveal the Origin of Differential Inhibition of Gag Polymorphic Viruses by HIV-1 Maturation InhibitorsCrystal structure of an HIV assembly and maturation switch.The structural biology of HIV assembly.The inhibition of assembly of HIV-1 virus-like particles by 3-O-(3',3'-dimethylsuccinyl) betulinic acid (DSB) is counteracted by Vif and requires its Zinc-binding domain.Polymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV- 1 maturation inhibitor bevirimatOn the role of the SP1 domain in HIV-1 particle assembly: a molecular switch?HIV-1 maturation inhibitor bevirimat stabilizes the immature Gag latticeAnalysis of the N-terminal region of the murine leukemia virus nucleocapsid proteinBevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection.Identification and Characterization of BMS-955176, a Second-Generation HIV-1 Maturation Inhibitor with Improved Potency, Antiviral Spectrum, and Gag Polymorphic Coverage.HIV-1 Capsid Inhibitors as Antiretroviral AgentsHIV-1 capsid assembly inhibitor (CAI) peptide: structural preferences and delivery into human embryonic lung cells and lymphocytesContributions of Charged Residues in Structurally Dynamic Capsid Surface Loops to Rous Sarcoma Virus Assembly.Impact of human immunodeficiency virus type 1 resistance to protease inhibitors on evolution of resistance to the maturation inhibitor bevirimat (PA-457)New small-molecule inhibitor class targeting human immunodeficiency virus type 1 virion maturation.Betulinic acid derivatives as human immunodeficiency virus type 2 (HIV-2) inhibitors.Insights into the activity of maturation inhibitor PF-46396 on HIV-1 clade CNew approaches for antiviral targeting of HIV assembly.Human Immunodeficiency Virus Gag and protease: partners in resistance.Synthesis and cytotoxicity of triterpenoids derived from betulin and betulinic acid via click chemistry.Triterpene derivatives that inhibit human immunodeficiency virus type 1 replication.Mutations in the spacer peptide and adjoining sequences in Rous sarcoma virus Gag lead to tubular budding.Susceptibility of human immunodeficiency virus type 1 to the maturation inhibitor bevirimat is modulated by baseline polymorphisms in Gag spacer peptide 1Update on the development of HIV entry inhibitors
P2860
Q21092230-D92546AF-8ECD-4D7E-AE9B-2179DB81B0DEQ21245046-D22A0771-6344-4D5D-A0A8-EB91D6F62E20Q21284351-7063AE2A-1315-4A36-B2DA-95B73C8A171AQ24606079-B82EA3C5-FA51-4E65-B72A-DB96E0FF9226Q24614498-5BC19E01-80FE-48B1-B218-78B593C8C289Q24642446-790D6251-BB5B-467C-92CB-20C42A84F271Q26771739-0BF67EF3-FBBF-406A-9432-E60FEBC0AB69Q27666929-7DC38FAE-9E15-494F-A97B-0C610A9AFE3EQ28477791-A7E1748F-D1B3-48AD-94C9-8EB1A60385C9Q28485054-B9416CA6-228F-40A7-889A-875CF340DBEFQ28554482-3FAA81E4-42CC-43E3-AB37-161CE77DDA0DQ30276365-2A481971-CE6B-48A5-8037-A4AA9CBC232FQ30437103-F502B328-22EB-45E7-AFC8-2026E5C07908Q30440445-5A5BA9D4-AB26-445F-A2E2-E8919597B872Q33864444-6DB784C9-C44E-4574-8772-C5CBE0AC154AQ34164929-BC8F16BF-509C-47A5-96CA-256DB8F1F6CCQ34529834-253A7A87-2DAA-4501-BCF1-20C9BB4C51ADQ34552402-9AFDEB9F-0D94-4C8A-ABDE-9CD7D1F45A14Q34885660-CE7E5066-FC44-4BA8-9ACF-DC873A1FFE58Q35992805-2F8A2293-D834-47CF-B36D-EEB82D994A24Q36672006-D5500693-4940-4796-8B6C-8A7F54088B5BQ36817934-28D71942-7F0B-4A76-B272-56108A82EBF0Q36950909-D799A447-AC62-4E26-A3B5-8ADB01D7DE62Q37192174-2E83846A-46DB-48D5-B657-50ED3A1C48EBQ37450688-80C417A4-4F14-467F-8AB5-658F79348F7CQ37459163-4828B6A7-2C95-4DF7-8F7F-F1C0BA9E5583Q37676344-8A08F192-BE88-4A0A-BF86-E3147A7DFFA9Q37901613-3099FA67-3BE0-43A6-B1C0-A6ED2B7C6BB9Q38032330-B35D130E-780A-40AC-ABBF-DF35325A98EAQ38941880-AD51D351-5A75-432E-8962-C47056B66A3BQ39630669-D9CEB06E-1160-44CF-B0EE-727A5A3B3E0FQ39763774-83BEC377-987C-4B88-8F6F-08B03F300A57Q42202820-E916F7AF-100D-4E78-8A2E-3D3DE56ED856Q58388992-6549E89B-9A66-45E5-8394-17C377C95954
P2860
Determinants of activity of the HIV-1 maturation inhibitor PA-457.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Determinants of activity of the HIV-1 maturation inhibitor PA-457.
@en
Determinants of activity of the HIV-1 maturation inhibitor PA-457.
@nl
type
label
Determinants of activity of the HIV-1 maturation inhibitor PA-457.
@en
Determinants of activity of the HIV-1 maturation inhibitor PA-457.
@nl
prefLabel
Determinants of activity of the HIV-1 maturation inhibitor PA-457.
@en
Determinants of activity of the HIV-1 maturation inhibitor PA-457.
@nl
P2093
P1433
P1476
Determinants of activity of the HIV-1 maturation inhibitor PA-457
@en
P2093
Abdul S Yunus
Carl T Wild
Claudia Matallana
David E Martin
Dorian Zoumplis
Eric O Freed
Graham P Allaway
Karl Salzwedel
Mary Reddick
P304
P356
10.1016/J.VIROL.2006.07.023
P407
P577
2006-08-22T00:00:00Z